Order Article Reprints

Kawakami H, Hironaka S, Esaki T, Chayama K, Tsuda M, Sugimoto N, Kadowaki S, Makiyama A, Machida N, Hirano H, et al. An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7). Cancers. 2021; 13(4):805. https://doi.org/10.3390/cancers13040805

Kawakami, Hisato, Shuichi Hironaka, Taito Esaki, Kazuaki Chayama, Masahiro Tsuda, Naotoshi Sugimoto, Shigenori Kadowaki, Akitaka Makiyama, Nozomu Machida, Hidekazu Hirano, and et al. 2021. "An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)" Cancers 13, no. 4: 805. https://doi.org/10.3390/cancers13040805

Kawakami, H., Hironaka, S., Esaki, T., Chayama, K., Tsuda, M., Sugimoto, N., Kadowaki, S., Makiyama, A., Machida, N., Hirano, H., Hirata, K., Hara, H., Yabusaki, H., Komatsu, Y., & Muro, K. (2021). An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7). Cancers, 13(4), 805. https://doi.org/10.3390/cancers13040805